Eloxx reports Phase 2 CF data: ELX-02 shows +2.83% ppFEV1 in 6 responders, supports pivotal trial

Eloxx Pharmaceuticals, Inc.

13 evaluable patients; 6 responders had +2.83% mean ppFEV1 increase at Day 35 vs Day 1.
Overall ppFEV1 change was -0.31% at Day 35; disease progression pre-treatment averaged -4.26%/yr.
Safety follow-up at 28 days showed -2.69% ppFEV1 decline; no treatment-related serious adverse events.
Results bolster decision to advance ELX-02 into pivotal Alport syndrome trial.
Interim topline from 11 patients reported Sep 2022; final analysis confirms activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.